JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (JCRRF) Financial Performance & Income Statement Overview
Review JCR Pharmaceuticals Co., Ltd. (JCRRF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
JCR Pharmaceuticals Co., Ltd. (JCRRF) Income Statement & Financial Overview
Explore comprehensive income reports for JCR Pharmaceuticals Co., Ltd. JCRRF, broken down by year and quarter.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $7.19B | $9.22B | $8.51B | $8.14B |
| Cost of Revenue | $4.37B | $2.68B | $2.26B | $2.29B |
| Gross Profit | $2.82B | $6.55B | $6.37B | $5.86B |
| Gross Profit Ratio | $0.39 | $0.71 | $0.75 | $0.72 |
| R&D Expenses | $5.51B | $3.35B | $3.40B | $0.00 |
| SG&A Expenses | $3.26B | $3.21B | $3.30B | $6.37B |
| Operating Expenses | $8.76B | $6.56B | $6.70B | $6.37B |
| Total Costs & Expenses | $13.14B | $9.24B | $8.96B | $8.65B |
| Interest Income | $22.00M | $0.00 | $41.00M | $27.00M |
| Interest Expense | $52.00M | $0.00 | $37.00M | $26.00M |
| Depreciation & Amortization | $868.00M | $799.25M | $841.00M | $826.00M |
| EBITDA | -$5.18B | $739.25M | -$47.00M | $1.22B |
| EBITDA Ratio | -$0.72 | $0.08 | -$0.006 | $0.15 |
| Operating Income | -$5.94B | -$15.00M | -$443.00M | -$510.00M |
| Operating Income Ratio | -$0.83 | -$0.002 | -$0.05 | -$0.06 |
| Other Income/Expenses (Net) | -$153.00M | $253.00M | -$482.00M | $73.00M |
| Income Before Tax | -$6.10B | $238.00M | -$925.00M | $369.00M |
| Income Before Tax Ratio | -$0.85 | $0.03 | -$0.11 | $0.05 |
| Income Tax Expense | -$1.88B | $36.00M | -$40.00M | $164.00M |
| Net Income | -$4.18B | $115.00M | -$891.00M | $201.00M |
| Net Income Ratio | -$0.58 | $0.01 | -$0.10 | $0.02 |
| EPS | -$33.80 | $0.93 | -$7.15 | $1.61 |
| Diluted EPS | -$33.80 | $0.94 | -$7.15 | $1.61 |
| Weighted Avg Shares Outstanding | $123.74M | $123.25M | $124.83M | $124.81M |
| Weighted Avg Shares Outstanding (Diluted) | $123.74M | $121.82M | $124.83M | $124.84M |
Over the last four quarters, JCR Pharmaceuticals Co., Ltd.'s revenue moved from $8.14B in Q1 2025 to $7.19B in Q4 2025. Operating income in Q4 2025 was -$5.94B, with a strong operating margin of -83%. Despite fluctuations in R&D and SG&A expenses, EBITDA for JCR Pharmaceuticals Co., Ltd. remained robust at -$5.18B, reflecting operational efficiency. Net income dropped to -$4.18B, with an EPS of -$33.80. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan